Compositions and methods for treating and preventing macular degeneration

• US 10,640,771 B2
• Filed: 04/17/2014
• Issued: 05/05/2020
• Est. Priority Date: 04/17/2013
• Status: Active Grant

• Current Assignee: Genzyme Corporation (Sanofi ), United States Department Of Health And Human Services
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Wadsworth, Samuel, Scaria, Abraham, Chan, Chi-Chao
• Primary Examiner(s): Epps-Smith, Janet L
• Application Number:
  US14/785,159
• Publication Number:
  US 20160068844A1
• Time in Patent Office: 2,210 Days
• Field of Search: 424 9321
• CPC Class Codes: A61K 38/1793 for cytokines; for lymphokines; for interferons
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector

Abstract

Compositions and methods for treating macular degeneration are disclosed. The methods utilize IL17 inhibitors, such as IL17 receptors, as well as fusion proteins including an IL17 receptor fused with a multimerization domain, and recombinant viral vectors encoding such fusions.

Claims

1. A method of treating or reducing age-related macular degeneration (AMD) in a mammalian subject comprising intravitreally administering to the diseased eye of the subject a composition comprising a recombinant viral vector encoding a fusion protein comprising an IL17 inhibitor and a multimerization domain, wherein the IL17 inhibitor is a soluble IL17A receptor capable of binding and modulating the activity of IL17A, wherein the recombinant viral vector is a recombinant adeno-associated virus serotype 2 (rAAV2) virion.

2. The method of claim 1, wherein the composition further comprises an opthalmalogically acceptable vehicle.

3. The method of claim 1, wherein the multimerization domain is derived from an immunoglobulin (Ig) heavy chain.

4. The method of claim 1, wherein the multimerization domain is derived from an immunoglobulin (Ig) constant region.

5. The method of claim 1, wherein the multimerization domain is derived from the Fc region of an immunoglobulin (Ig).

6. The method of claim 1, wherein the multimerization domain comprises the CH3 of an immunoglobulin (Ig).

7. The method of claim 1, wherein the multimerization domain is derived from an IgG1, an IgG2, an IgG3 or an IgG4.

8. The method of claim 1, wherein the multimerization domain is from the constant region of an IgG1 heavy chain.

9. The method of claim 1, wherein when the fusion protein is expressed, a multimer of the fusion protein is produced.

10. The method of claim 1, wherein the recombinant vector encodes a fusion protein comprising:

(a) an IL17A receptor; and

(b) an immunoglobulin constant region multimerization domain,

wherein when the fusion protein is expressed, a multimer of the fusion protein is produced.

11. The method of claim 10, wherein the multimerization domain comprises the CH3 domain of an IgG, or an active fragment thereof.

12. The method of claim 10, wherein the multimerization domain is from an IgG1, an IgG2, an IgG3 or an IgG4.

13. The method of claim 10, wherein the multimerization domain is from the constant region of an IgG1 heavy chain.

14. The method of claim 10, wherein the multimer is a homodimer.

15. The method of claim 10, wherein the fusion protein comprises the amino acid sequence of FIG. 3B (SEQ ID NO:

4), or an active variant thereof having at least 90% sequence identity to the sequence of FIG. 3B (SEQ ID NO;

4).

16. The rAAV virion contains an AAV2 serotype capsid and an AAV2 ITR.